Differentiation factors and cytokines in the atherosclerotic plaque micro-environment as a trigger for macrophage polarisation

Thrombosis and Haemostasis

Volumn 106, Issue 5, 2011, Pages 763-771

  Wolfs, Ine M J ^a   Donners, Marjo M P C ^a   de Winther, Menno P J ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Atherosclerosis; Cytokines; Macrophage heterogeneity; Micro environment; Polarisation

Indexed keywords

ABC TRANSPORTER A1; ARGINASE; ARGINASE 1; ARGINASE II; CD14 ANTIGEN; CD16 ANTIGEN; CD163 ANTIGEN; CD68 ANTIGEN; CHEMOKINE; CHOLESTEROL; COLONY STIMULATING FACTOR 1; CXCL4 CHEMOKINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 4; LIVER X RECEPTOR ALPHA; MACROPHAGE MANNOSE RECEPTOR; MANNOSE RECEPTOR; OXIDIZED LOW DENSITY LIPOPROTEIN; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ARTICLE; ATHEROSCLEROTIC PLAQUE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL HETEROGENEITY; CELL POLARITY; CHOLESTEROL TRANSPORT; CHRONIC INFLAMMATION; FOAM CELL; HUMAN; INTERFERON PRODUCTION; M1 MACROPHAGE; M2 MACROPHAGE; MACROPHAGE; MACROPHAGE ACTIVATION; MACROPHAGE FUNCTION; MICROENVIRONMENT; NATURAL KILLER CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TH1 CELL; TH2 CELL; TISSUE REPAIR;

ANIMALS; ARTERIES; ATHEROSCLEROSIS; CELL DIFFERENTIATION; CELLULAR MICROENVIRONMENT; CYTOKINES; FOAM CELLS; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; LIPID METABOLISM; MACROPHAGE ACTIVATION; MACROPHAGES; PHENOTYPE; T-LYMPHOCYTES;

EID: 80155214124     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH11-05-0320     Document Type: Article

References (72)

1. Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol 2008; 8: 958-969.
2. Gordon S, Martinez FO. Alternative activation of macrophages: mechanism and functions. Immunity 2010; 32: 593-604.
3. Martinez FO, Sica A, Mantovani A, et al. Macrophage activation and polarization. Front Biosci 2008; 13: 453-461.
4. Krausgruber T, Blazek K, Smallie T, et al. IRF5 promotes inflammatory macrophage polarization and TH1-TH17 responses. Nat Immunol 2011; 12: 231-238.
5. El Chartouni C, Schwarzfischer L, Rehli M. Interleukin-4 induced interferon regulatory factor (Irf) 4 participates in the regulation of alternative macrophage priming. Immunobiology 2010; 215: 821-825.
6. Sinha P, Clements VK, Ostrand-Rosenberg S. Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease. J Immunol 2005; 174: 636-645.
7. Porta C, Rimoldi M, Raes G, et al. Tolerance and M2 (alternative) macrophage polarization are related processes orchestrated by p50 nuclear factor kappaB. Proc Natl Acad Sci USA 2009; 106: 14978-14983.
8. Bouhlel MA, Derudas B, Rigamonti E, et al. PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties. Cell Metab 2007; 6: 137-143.
9. Sica A, Larghi P, Mancino A, et al. Macrophage polarization in tumour progression. Semin Cancer Biol 2008; 18: 349-355.
10. Tidball JG, Villalta SA. Regulatory interactions between muscle and the immune system during muscle regeneration. Am J Physiol Regul Integr Comp Physiol 2010; 298: R1173-1187.
11. Lee S, Huen S, Nishio H, et al. Distinct macrophage phenotypes contribute to kidney injury and repair. J Am Soc Nephrol 2011; 22: 317-326.
12. Kadl A, Meher AK, Sharma PR, et al. Identification of a novel macrophage phenotype that develops in response to atherogenic phospholipids via Nrf2. Circ Res 2010; 107: 737-746.
13. Gleissner CA, Shaked I, Little KM, et al. CXC chemokine ligand 4 induces a unique transcriptome in monocyte-derived macrophages. J Immunol 2010; 184: 4810-4818.
14. Geissmann F, Jung S, Littman DR. Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity 2003; 19: 71-82.
15. Auffray C, Sieweke MH, Geissmann F. Blood monocytes: development, heterogeneity, and relationship with dendritic cells. Annu Rev Immunol 2009; 27: 669-692.
16. Swirski FK, Libby P, Aikawa E, et al. Ly-6Chi monocytes dominate hypercholesterolemia- associated monocytosis and give rise to macrophages in atheromata. J Clin Invest 2007; 117: 195-205.
17. Tacke F, Alvarez D, Kaplan TJ, et al. Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques. J Clin Invest 2007; 117: 185-194.
18. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352: 1685-1695.
19. Weber C, Zernecke A, Libby P. The multifaceted contributions of leukocyte subsets to atherosclerosis: lessons from mouse models. Nat Rev Immunol 2008; 8: 802-815.
20. Gijbels MJ, van der Cammen M, van der Laan LJ, et al. Progression and regression of atherosclerosis in APOE3-Leiden transgenic mice: an immunohistochemical study. Atherosclerosis 1999; 143: 15-25.
21. Poston RN, Hussain IF. The immunohistochemical heterogeneity of atheroma macrophages: comparison with lymphoid tissues suggests that recently blood-derived macrophages can be distinguished from longer-resident cells. J Histochem Cytochem 1993; 41: 1503-1512.
22. Stoger JL, Goossens P, de Winther MP. Macrophage heterogeneity: relevance and functional implications in atherosclerosis. Curr Vasc Pharmacol 2010; 8: 233-248.
23. van der Wal AC, Das PK, Bentz van de Berg D, et al. Atherosclerotic lesions in humans. In situ immunophenotypic analysis suggesting an immune mediated response. Lab Invest 1989; 61: 166-170.
24. Chinetti-Gbaguidi G, Baron M, Bouhlel MA, et al. Human Atherosclerotic Plaque Alternative Macrophages Display Low Cholesterol Handling but High Phagocytosis Because of Distinct Activities of the PPAR{gamma} and LXRα Pathways. Circ Res 2011; 108: 985-995.
25. Komohara Y, Hirahara J, Horikawa T, et al. AM-3K, an anti-macrophage antibody, recognizes CD163, a molecule associated with an anti-inflammatory macrophage phenotype. J Histochem Cytochem 2006; 54: 763-771.
26. Buechler C, Ritter M, Orso E, et al. Regulation of scavenger receptor CD163 expression in human monocytes and macrophages by pro- and antiinflammatory stimuli. J Leukoc Biol 2000; 67: 97-103.
27. Boyle JJ, Harrington HA, Piper E, et al. Coronary intraplaque hemorrhage evokes a novel atheroprotective macrophage phenotype. Am J Pathol 2009; 174: 1097-1108.
28. Sindrilaru A, Peters T, Wieschalka S, et al. An unrestrained proinflammatory M1 macrophage population induced by iron impairs wound healing in humans and mice. J Clin Invest 2011; 121: 985-997.
29. Khallou-Laschet J, Varthaman A, Fornasa G, et al. Macrophage plasticity in experimental atherosclerosis. PLoS One 2010; 5: e8852.
30. Feig JE, Parathath S, Rong JX, et al. Reversal of hyperlipidemia with a genetic switch favorably affects the content and inflammatory state of macrophages in atherosclerotic plaques. Circulation 2011; 123: 989-998.
31. Loke P, Gallagher I, Nair MG, et al. Alternative activation is an innate response to injury that requires CD4+ T cells to be sustained during chronic infection. J Immunol 2007; 179: 3926-3936.
32. Hiasa M, Abe M, Nakano A, et al. GM-CSF and IL-4 induce dendritic cell differentiation and disrupt osteoclastogenesis through M-CSF receptor shedding by up-regulation of TNF-alpha converting enzyme (TACE). Blood 2009; 114: 4517-4526.
33. Verreck FA, de Boer T, Langenberg DM, et al. Human IL-23-producing type 1 macrophages promote but IL-10-producing type 2 macrophages subvert immunity to (myco)bacteria. Proc Natl Acad Sci USA 2004; 101: 4560-4565.
34. Hamilton JA. Colony-stimulating factors in inflammation and autoimmunity. Nat Rev Immunol 2008; 8: 533-544.
35. Brocheriou I, Maouche S, Durand H, et al. Antagonistic regulation of macrophage phenotype by M-CSF and GM-CSF: implication in atherosclerosis. Atherosclerosis 2011; 214: 316-324.
36. Fleetwood AJ, Lawrence T, Hamilton JA, et al. Granulocyte-macrophage colonystimulating factor (CSF) and macrophage CSF-dependent macrophage phenotypes display differences in cytokine profiles and transcription factor activities: implications for CSF blockade in inflammation. J Immunol 2007; 178: 5245-5252.
37. van Tits LJ, Stienstra R, van Lent PL, et al. Oxidized LDL enhances pro-inflammatory responses of alternatively activated M2 macrophages: a crucial role for Kruppel- like factor 2. Atherosclerosis 2011; 214: 345-349.
38. Waldo SW, Li Y, Buono C, et al. Heterogeneity of human macrophages in culture and in atherosclerotic plaques. Am J Pathol 2008; 172: 1112-1126.
39. Sierra-Filardi E, Vega MA, Sanchez-Mateos P, et al. Heme Oxygenase-1 expression in M-CSF-polarized M2 macrophages contributes to LPS-induced IL-10 release. Immunobiology 2010; 215: 788-795.
40. Xu W, Schlagwein N, Roos A, et al. Human peritoneal macrophages show functional characteristics of M-CSF-driven anti-inflammatory type 2 macrophages. Eur J Immunol 2007; 37: 1594-1599.
41. Filonzi EL, Zoellner H, Stanton H, et al. Cytokine regulation of granulocyte-macrophage colony stimulating factor and macrophage colony-stimulating factor production in human arterial smooth muscle cells. Atherosclerosis 1993; 99: 241-252.
42. Sakai M, Biwa T, Matsumura T, et al. Glucocorticoid inhibits oxidized LDL-induced macrophage growth by suppressing the expression of granulocyte/macrophage colony-stimulating factor. Arterioscler Thromb Vasc Biol 1999; 19: 1726-1733.
43. Liao F, Berliner JA, Mehrabian M, et al. Minimally modified low density lipoprotein is biologically active in vivo in mice. J Clin Invest 1991; 87: 2253-2257.
44. Plenz G, Koenig C, Severs NJ, et al. Smooth muscle cells express granulocyte-macrophage colony-stimulating factor in the undiseased and atherosclerotic human coronary artery. Arterioscler Thromb Vasc Biol 1997; 17: 2489-2499.
45. Frostegard J, Ulfgren AK, Nyberg P, et al. Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage- stimulating cytokines. Atherosclerosis 1999; 145: 33-43.
46. Kazawa T, Kawasaki T, Sakamoto A, et al. Expression of liver X receptor alpha and lipid metabolism in granulocyte-macrophage colony-stimulating factor-induced human monocyte-derived macrophage. Pathol Int 2009; 59: 152-160.
47. Irvine KM, Andrews MR, Fernandez-Rojo MA, et al. Colony-stimulating factor-1 (CSF-1) delivers a proatherogenic signal to human macrophages. J Leukoc Biol 2009; 85: 278-288.
48. Hansson GK, Holm J, Jonasson L. Detection of activated T lymphocytes in the human atherosclerotic plaque. Am J Pathol 1989; 135: 169-175.
49. de Boer OJ, van der Wal AC, Verhagen CE, et al. Cytokine secretion profiles of cloned T cells from human aortic atherosclerotic plaques. J Pathol 1999; 188: 174-179.
50. Geng YJ, Holm J, Nygren S, et al. Expression of the macrophage scavenger receptor in atheroma. Relationship to immune activation and the T-cell cytokine interferon- gamma. Arterioscler Thromb Vasc Biol 1995; 15: 1995-2002.
51. Uyemura K, Demer LL, Castle SC, et al. Cross-regulatory roles of interleukin (IL)-12 and IL-10 in atherosclerosis. J Clin Invest 1996; 97: 2130-2138.
52. Mallat Z, Heymes C, Ohan J, et al. Expression of interleukin-10 in advanced human atherosclerotic plaques: relation to inducible nitric oxide synthase expression and cell death. Arterioscler Thromb Vasc Biol 1999; 19: 611-616.
53. Kleemann R, Zadelaar S, Kooistra T. Cytokines and atherosclerosis: a comprehensive review of studies in mice. Cardiovasc Res 2008; 79: 360-376.
54. Tedgui A, Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev 2006; 86: 515-581.
55. King VL, Cassis LA, Daugherty A. Interleukin-4 does not influence development of hypercholesterolemia or angiotensin II-induced atherosclerotic lesions in mice. Am J Pathol 2007; 171: 2040-2047.
56. Zhou X, Paulsson G, Stemme S, et al. Hypercholesterolemia is associated with a T helper (Th) 1/Th2 switch of the autoimmune response in atherosclerotic apo E-knockout mice. J Clin Invest 1998; 101: 1717-1725.
57. Davenport P, Tipping PG. The role of interleukin-4 and interleukin-12 in the progression of atherosclerosis in apolipoprotein E-deficient mice. Am J Pathol 2003; 163: 1117-1125.
58. Pinderski LJ, Fischbein MP, Subbanagounder G, et al. Overexpression of interleukin- 10 by activated T lymphocytes inhibits atherosclerosis in LDL receptor-deficient Mice by altering lymphocyte and macrophage phenotypes. Circ Res 2002; 90: 1064-1071.
59. Nakagawa T, Nozaki S, Nishida M, et al. Oxidized LDL increases and interferongamma decreases expression of CD36 in human monocyte-derived macrophages. Arterioscler Thromb Vasc Biol 1998; 18: 1350-1357.
60. Panousis CG, Zuckerman SH. Regulation of cholesterol distribution in macrophage- derived foam cells by interferon-gamma. J Lipid Res 2000; 41: 75-83.
61. Geng YJ, Hansson GK. Interferon-gamma inhibits scavenger receptor expression and foam cell formation in human monocyte-derived macrophages. J Clin Invest 1992; 89: 1322-1330.
62. Wang XQ, Panousis CG, Alfaro ML, et al. Interferon-gamma-mediated downregulation of cholesterol efflux and ABC1 expression is by the Stat1 pathway. Arterioscler Thromb Vasc Biol 2002; 22: e5-9.
63. Panousis CG, Zuckerman SH. Interferon-gamma induces downregulation of Tangier disease gene (ATP-binding-cassette transporter 1) in macrophage-derived foam cells. Arterioscler Thromb Vasc Biol 2000; 20: 1565-1571.
64. Brand K, Mackman N, Curtiss LK. Interferon-gamma inhibits macrophage apolipoprotein E production by posttranslational mechanisms. J Clin Invest 1993; 91: 2031-2039.
65. Reiss AB, Awadallah NW, Malhotra S, et al. Immune complexes and IFN-gamma decrease cholesterol 27-hydroxylase in human arterial endothelium and macrophages. J Lipid Res 2001; 42: 1913-1922.
66. Feng J, Han J, Pearce SF, et al. Induction of CD36 expression by oxidized LDL and IL-4 by a common signaling pathway dependent on protein kinase C and PPARgamma. J Lipid Res 2000; 41: 688-696.
67. Cornicelli JA, Butteiger D, Rateri DL, et al. Interleukin-4 augments acetylated LDL-induced cholesterol esterification in macrophages. J Lipid Res 2000; 41: 376-383.
68. Halvorsen B, Waehre T, Scholz H, et al. Interleukin-10 enhances the oxidized LDLinduced foam cell formation of macrophages by antiapoptotic mechanisms. J Lipid Res 2005; 46: 211-219.
69. Han X, Kitamoto S, Lian Q, et al. Interleukin-10 facilitates both cholesterol uptake and efflux in macrophages. J Biol Chem 2009; 284: 32950-32958.
70. Han X, Kitamoto S, Wang H, et al. Interleukin-10 overexpression in macrophages suppresses atherosclerosis in hyperlipidemic mice. FASEB J 2010; 24: 2869-2880.
71. Rubic T, Lorenz RL. Downregulated CD36 and oxLDL uptake and stimulated ABCA1/G1 and cholesterol efflux as anti-atherosclerotic mechanisms of interleukin-10. Cardiovasc Res 2006; 69: 527-535.
72. Lin J, Li M, Wang Z, et al. The role of CD4+CD25+ regulatory T cells in macrophage- derived foam-cell formation. J Lipid Res 2010; 51: 1208-1217.